Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

25.33 -3.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.33

Massimo

26.35

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+54.78% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

892M

2.9B

Apertura precedente

28.5

Chiusura precedente

25.33

Notizie sul Sentiment di mercato

By Acuity

38%

62%

94 / 339 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2026, 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

8 set 2026, 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

8 set 2026, 23:46 UTC

News
Social Media

Warner Bros Discovery Inc. shares are higher in after-market hours following Paramount Skydance's court filings on merger progress, indicating potential $1.88 billion impact.

8 set 2026, 23:41 UTC

News

BJ's Restaurants shares are trading lower in after-market hours following a presentation at the Barclays Consumer Staples Conference focused on a strategic reset.

8 set 2026, 23:41 UTC

News

Boston Beer Company appointed Allison Stransky as Chief Marketing Officer, effective October 12, 2026. Shares are trading higher in after-market hours.

8 set 2026, 23:41 UTC

News

Goldman Sachs has agreed to acquire NEOS Investments for $2.25 billion, with shares trading lower in after-market hours following the announcement.

8 set 2026, 23:36 UTC

News
Correlated Moves

Piper Sandler initiated coverage of Quanta Services with an Overweight rating. Shares rose in after-market trading, closing at $624.41.

8 set 2026, 23:36 UTC

News

Shutterstock Inc appointed three new board members to enhance governance. Shares are trading higher after the announcement of Timothy Adams, Matthew Salzberg, and Michael Thompson.

8 set 2026, 23:36 UTC

News

Air Products and Chemicals reported stronger third-quarter profitability, boosting full-year guidance. Shares traded higher in after-market hours following the results.

8 set 2026, 23:31 UTC

News

NetApp shares are trading higher in after-market hours following CEO George Kurian's discussion at the Goldman Sachs Communacopia + Technology Conference.

8 set 2026, 23:31 UTC

News

Estee Lauder Companies announced expanded leadership roles for Brian Franz and Amber English. Shares traded lower during after-market hours following the news.

8 set 2026, 23:21 UTC

News

Prestige Consumer Healthcare Inc shares are lower in after-market trading amid geopolitical tensions and inflation concerns affecting market sentiment across sectors.

8 set 2026, 23:21 UTC

News

Target Corp shares are higher in after-market trading, supported by recent turnaround efforts despite an analyst downgrade to a hold rating.

8 set 2026, 23:21 UTC

News

Tapestry Inc gains in after-market trading, with a market cap of $23.69 billion. A $100 investment five years ago is now worth approximately $290.54.

8 set 2026, 23:16 UTC

News

Stanley Black & Decker shares are higher in after-market trading following the announcement of CEO Chris Nelson's upcoming presentation at a Morgan Stanley conference.

8 set 2026, 23:11 UTC

News

Travel + Leisure Co shares are higher in after-market hours following the announcement of CFO Erik Hoag's participation in a Goldman Sachs conference on September 14, 2026.

8 set 2026, 23:06 UTC

News

Lowe's CEO Marvin R. Ellison will participate in a Goldman Sachs conference on September 15, 2026. Shares are higher in after-market trading.

8 set 2026, 23:06 UTC

Social Media
News
Correlated Moves

Citigroup plans to offer instant cross-border payments using blockchain technology for Japanese firms. Shares are higher in after-market trading following the announcement.

8 set 2026, 23:06 UTC

Social Media
News

General Electric shares rise in after-market hours amid interest in strategic developments, including a $11.75 billion acquisition and potential valuation boost for Precision Castparts.

8 set 2026, 23:06 UTC

News

Eli Lilly's Mounjaro received FDA approval to reduce heart-attack and stroke risk in adults with type 2 diabetes. Shares advanced slightly in after-market trading.

8 set 2026, 23:06 UTC

News

NextEra Energy Inc. shares are trading higher in after-market hours as management announces investor meetings to discuss growth expectations and the Dominion Energy merger.

8 set 2026, 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

8 set 2026, 23:06 UTC

News

General Mills has filed an antitrust lawsuit against major U.S. sugar producers for alleged price collusion, with shares trading higher in after-market hours.

8 set 2026, 23:06 UTC

News

VICI Properties Inc. shares are trading higher in after-market hours following the release of its 2025-2026 Corporate Responsibility Report, highlighting sustainability efforts.

8 set 2026, 23:06 UTC

Event
News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

8 set 2026, 23:01 UTC

Social Media
News

AT&T's CEO highlights growth potential and $45B shareholder return plan at Goldman Sachs conference; shares rise in after-market hours.

8 set 2026, 23:01 UTC

News

Ares Capital Corp priced a $750 million public offering of unsecured notes, aiming to enhance financial flexibility. Shares are trading higher in after-market hours.

8 set 2026, 23:01 UTC

News

Constellation Brands plans to redeem $600 million in Senior Notes due 2027, contributing to a rise in shares during after-market trading.

8 set 2026, 23:01 UTC

Correlated Moves
News
Event
Social Media

Braze Inc shares fell sharply in after-hours trading despite strong second-quarter results, as weaker third-quarter EPS guidance raised investor concerns.

8 set 2026, 23:01 UTC

Social Media
News

GameStop shares fell in after-hours trading despite reporting adjusted EPS of $0.27 and raising its fiscal year 2026 EBITDA outlook to over $650 million.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

54.78% in crescita

Previsioni per 12 mesi

Media 39.33 USD  54.78%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

94 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat